A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma Save

Date Added
May 7th, 2019
PRO Number
Pro00088579
Researcher
Andrea Abbott

List of Studies

Silhouette
Keywords
Cancer, Cancer/Skin
Summary

This study is for participants that have been diagnosed with clinically detectable stage III-IV high-risk Melanoma. The investigational drug in this study is pembrolizumab. The purpose of this study is to compare outcomes of receiving the study drug either before and after or only after surgery for your type of cancer. Participants can expect to be followed for up to 10 years after they register to the study.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

INCREASING SOCIOECONOMICALLY DISADVANTAGED PATIENTS' ENGAGEMENT IN BREAST CANCER SURGERY DECISIONMAKING THROUGH A SHARED DECISION MAKING INTERVENTION Save

Date Added
April 10th, 2019
PRO Number
Pro00087587
Researcher
Andrea Abbott

List of Studies

Silhouette
Keywords
Cancer/Breast
Summary

This study is for breast cancer patients who are making decisions about breast cancer surgery. This study is being done to learn about how patients and their surgeons make decisions about breast cancer surgery.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login